首页> 外文期刊>World Journal of Gastroenterology >Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea.
【24h】

Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea.

机译:益生菌(Saccharomyces boulardii)在管理和预防腹泻中的作用。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To assess the efficacy and safety of Saccharomyces boulardii (S. boulardii) in acute watery diarrhoea and its role in reducing the frequency of episodes of diarrhoea in subsequent two months. METHODS: Children from 2 mo to 12 years of age, with acute diarrhoea were selected according to inclusion criteria and randomised in S. boulardii group (treated with ORS, nutritional support and S. boulardii, 250 mg bid) and in control group (treated with ORS and nutritional support only). Active treatment phase was 5 d and each child was followed for two months afterwards. Frequency and consistency of stools as well as safety of drug was assessed on every visit. A comparison of two groups was done in terms of number of diarrhoeal episode in subsequent two months. RESULTS: There were fifty patients in each group. Baseline characteristics such as mean age and the average frequency of stools were comparable in S. boulardii and control group at the time of inclusion in the trial. By d 3 it reduced to 2.7 and 4.2stools per d respectively and by d 6 it reduced to 1.6 (S. boulardii Group) and 3.3 (control group). The duration of diarrhoea was 3.6 d in S. boulardii group whereas it was 4.8 d in control group (P = 0.001). In the following two months, S. boulardii group had a significantly lower frequency of 0.54 episodes as compared to 1.08 episodes in control group. The drug was well accepted and tolerated. There were no reports of the side effects during treatment period. CONCLUSION: S. boulardii significantly reduces the frequency and duration of acute diarrhoea. The consistency of stool also improves. The drug is well-tolerated.
机译:目的:评估布尔糖酵母(S. boulardii)在急性水样腹泻中的功效和安全性,以及其在随后两个月中减少腹泻次数的作用。方法:根据入选标准,选择2个月至12岁的急性腹泻患儿,随机分为S. boulardii组(口服ORS,营养支持和S. boulardii,250 mg bid)和对照组(治疗)。仅使用ORS和营养支持)。积极治疗阶段为5天,此后每个孩子接受随访两个月。每次就诊时评估大便的频率和稠度以及药物的安全性。在随后两个月的腹泻发作次数方面对两组进行了比较。结果:每组有50名患者。在纳入试验时,S。boulardii和对照组的基线特征(例如平均年龄和大便的平均频率)相当。到第3天,它分别减少到每天2.7和4.2大便;到第6天,它减少到1.6(S。boulardii组)和3.3(对照组)。猪链球菌腹泻时间为3.6 d,而对照组腹泻时间为4.8 d(P = 0.001)。在接下来的两个月中,与对照组的1.08次发作相比,布拉迪链球菌组的发作频率为0.54次明显更低。该药物被广泛接受和耐受。没有关于治疗期间副作用的报道。结论:猪痢疾链球菌显着减少了急性腹泻的发生频率和持续时间。粪便的稠度也得到改善。该药耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号